OUTLINE: This is a multicenter, dose-finding study of cyclophosphamide.
engraftment and < 1 of 10 patients experiences dose-limiting toxicity.
- Allogeneic bone marrow transplantation (BMT): Patients undergo allogeneic BMT on day 0.